Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi


  • M. Kathryn Brewer
  • Amanda R. Sherwood
  • Vikas V. Dukhande
  • Matthew S. Gentry
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_603


Historical Background

Two groups searching for genes mutated in Lafora disease patients independently discovered the EPM2A (epilepsy, progressive myoclonic type 2A) gene, and the protein it encoded was aptly named laforin (Serratosa et al. 1995; Minassian et al. 1998). Laforin is a bimodular protein containing a dual specificity phosphatase (DSP) domain and a carbohydrate-binding module (CBM) (Fig. 1) (Minassian et al. 1998, Wang et al. 2002). Dual specificity phosphatases (DSPs) are a diverse group of phosphatases whose members dephosphorylate phosphoserine/phosphothreonine (pSer/pThr), phosphotyrosine (pTyr), phosphoinositols, ribo/deoxyribonucleotide 5′-triphosphates, pyrophosphate/triphosphate, or phosphoglucans. DSPs are members of the larger protein tyrosine phosphatase (PTP) superfamily that all utilize a cysteine-dependent mechanism to hydrolyze phosphoester bonds (Tonks 2006). This mechanism is dependent on the conserved CX5R active site motif common to all PTP phosphatases. Laforin is the founding member of a small group within the DSPs called the glucan phosphatases, which liberate phosphate from glucans such as glycogen. CBMs are divided into 80 families based on primary, secondary, and, when available, tertiary structure (Cantarel et al. 2009). In addition to binding and dephosphorylating glucans, laforin also appears to act as a scaffolding protein (Gentry et al. 2013). The gene encoding laforin is conserved in all vertebrates and in a subset of protists and invertebrates (Gentry et al. 2007; Gentry and Pace 2009). Mutations in the gene encoding laforin result in a fatal disease called Lafora disease (LD).
Laforin, Fig. 1

A schematic of laforin. Laforin contains an amino-terminal carbohydrate-binding module (CBM) followed by a dual specificity phosphatase (DSP) domain. Lafora disease missense mutations affect residues throughout the protein and have differential effects on laforin activity

Lafora Disease

Lafora disease (LD) is a fatal neurodegenerative epilepsy that is autosomal recessive and is characterized by rapid neurological deterioration. LD is one of five diseases that represent the inherited progressive myoclonus epilepsy (PME) family (Berkovic et al. 1986, 1991; Girard et al. 2013). Due to the progressive nature of neurodegeneration, the frequency of myoclonic seizures, and the variety of seizure types that can present, PMEs are often difficult to diagnose at onset (reviewed in Minassian 2001).

LD is characterized by myoclonic, tonic-clonic, and focal-occipital seizures among other seizure types that increase in frequency and severity with age, with the first tonic-clonic epileptic presentation occurring in late childhood or early adolescence. Other symptoms include dementia, visual hallucinations, ataxia, absence, and grand mal seizures along with epilepsy triggered by stimulus (reviewed in Minassian 2001). Death occurs approximately 10 years following initial onset due to complications such as status epilepticus, aspiration pneumonia, or respiratory failure. There is significant neuronal loss across the CNS upon autopsy (reviewed in Minassian 2001; Ganesh et al. 2006).

Approximately 60% of LD cases result from missense mutations, nonsense mutations, deletions, or insertions in the EPM2A gene encoding laforin. LD-associated missense mutations are scattered throughout the protein, and multiple studies have shown that these mutations disrupt phosphatase activity, glycogen binding, dimerization, protein-protein interactions, or localization (Fig. 1) (Wang et al. 2002; Gentry et al. 2007; Roma-Mateo et al. 2011; Wang and Roach 2004; Fernandez-Sanchez et al. 2003; Tagliabracci et al. 2007; Raththagala et al. 2015; Ganesh et al. 2004). LD also results from mutations in the EPM2B (epilepsy, progressive myoclonic type 2B) gene encoding the E3 ubiquitin ligase malin (Chan et al. 2003).

A hallmark of LD is the presence of insoluble polyglucosan bodies termed Lafora bodies (LBs) in the cytoplasm of cells from most tissues. These tissues, including neurons, cardiac muscle, and liver, are also tissues that display highest laforin expression in normal individuals (reviewed in Ganesh et al. 2006). The spherical LB inclusions are 3–40 μm in size and can grow large enough to occupy the entire cytoplasm. The inclusions found in LD contain only a small amount of ubiquitinated protein and are instead composed of improperly branched and hyperphosphorylated glucose moieties. Despite the presence of LBs in a variety of tissues throughout the body, neurological symptoms predominate (reviewed in Minassian 2001).

Laforin Expression, Isoforms, and Localization

Laforin mRNA is widely expressed in the human body. All tissues examined contain laforin mRNA, including: brain, heart, skeletal muscle, liver, lung, placenta, kidney, testis, spleen, thymus, prostate, ovary, small intestine, and pancreas (Minassian et al. 1998). Various brain regions such as the cerebellum, cortex, medulla, putamen, and spinal cord also express laforin transcript at similar levels, demonstrating the ubiquitous expression of laforin in the brain (Ganesh et al. 2001).

The sequences of nine splice variants of the EPM2A gene are available in the Universal Protein Resource (www.uniprot.org), and five isoforms have been biochemically characterized (Dubey et al. 2012; Dubey and Ganesh 2008). The dominant splice variant codes for a 331 amino acid product which has phosphatase activity, binds to glycogen, dimerizes, and interacts with malin; other isoforms, which possess various combinations of these characteristics, may function to regulate the activity or localization of the dominant isoform (Dubey and Ganesh 2008; Ganesh et al. 2002). The dominant 331 amino acid isoform is the best characterized and the one discussed throughout this review.

It was initially observed that overexpressed laforin was largely found in the cytosol with some signs of endoplasmic reticulum (ER) localization, and lower levels are found in the nucleus (Ganesh et al. 2000, 2002; Minassian et al. 2001). Later it was shown that laforin interacts with glycogen in vitro and in vivo, and overexpressed laforin colocalizes with sites of glycogen synthesis in cells, which are cytosolic and associated with the ER (Wang et al. 2002; Tiberia et al. 2012). Mutations in the CBM disrupt glycogen colocalization, and are found in the nucleus (Wang et al. 2002; Singh et al. 2012). Laforin localization appears to be determined by the presence of glycogen. One study reported that laforin translocates from the nucleus to the cytoplasm upon glucose uptake and glycogen synthesis in cell culture (Singh et al. 2012). They showed that cytoplasmic translocation of laforin is suppressed in the presence of forskolin, which promotes glycogen degradation despite high glucose, and maintained in the presence of glucosamine, which prevents glycogen breakdown despite the absence of glucose (Singh et al. 2012). Other studies show that overexpressed and endogenous laforin sediments with microsomal/glycogen particle fractions during high-speed centrifugation (Fernandez-Sanchez et al. 2003; Tiberia et al. 2012). Studies of laforin in mouse models have confirmed that glycogen and laforin levels are positively correlated (see “Regulation of Laforin Activity and Concentration”). Furthermore, glycogen metabolic enzymes such as glycogen synthase (GS) and protein targeting to glycogen (PTG/R5) also localize to glycogen granules, and in addition to colocalizing with them, laforin has been shown to interact with these enzymes using yeast two-hybrid screening and immunoprecipitation, and may participate in their regulation (See “Interaction and Signaling”) (Fernandez-Sanchez et al. 2003). These studies strongly suggest laforin is part of a complex of enzymes on the granule that regulate its synthesis and degradation.

Laforin Phosphatase Activity

Consistent with its classification as a DSP, laforin exhibits in vitro phosphatase activity against pSer, pThr, and pTyr residues and can utilize the artificial substrates 3-O-methylflourescein phosphate (OMFP) and para-nitrophenyl phosphate (p-NPP) (Dukhande et al. 2010; Sherwood et al. 2013; Roma-Mateo et al. 2016). Although binding partners for laforin were identified, laforin’s substrate remained elusive at first. Dixon and colleagues first identified that laforin contains a CBM and demonstrated that this domain allows laforin to bind glucans (Wang et al. 2002). Out of 65 dual specificity phosphatases, laforin is the only DSP with a CBM (Tonks 2006). This fact coupled with a finding from the 1960s that LBs have increased phosphate prompted Gentry and colleagues to test if laforin could liberate phosphate from glucans. Laforin does indeed dephosphorylate glucans, while other DSPs and phosphatases from other families lack this activity (Sherwood et al. 2013; Worby et al. 2006). This was the first description of an enzyme that released phosphate from carbohydrates, establishing laforin as the founding member of the glucan phosphatase family. It was subsequently demonstrated that laforin can bind and dephosphorylate glycogen, its glucan activity is unique to laforin among vertebrate DSPs, and laforin orthologs from other organisms also possess phosphatase activity (Gentry and Pace 2009; Tagliabracci et al. 2007, Raththagala et al. 2015; Sherwood et al. 2013; Brewer et al. 2014). There are two other glucan phosphatases in plants, Starch Excess 4 (SEX4) and Like SEX Four 2 (LSF2) (Santelia et al. 2011; Kotting et al. 2009; Meekins et al. 2016). SEX4, LSF2, and laforin make up the glucan phosphatase family (reviewed in Emanuelle et al. 2016; Gentry et al. 2016). SEX4 also contains a CBM and DSP, though in the reverse orientation, and laforin and SEX4 are functional homologs since SEX4 deficiency in plants can be partially complemented by laforin (Gentry et al. 2007).

The identification of laforin as a glucan phosphatase explains how loss of laforin leads to increased phosphate content in glycogen (Tagliabracci et al. 2007; Sakai et al. 1970). But why does increased phosphate lead to glycogen accumulation and LB formation? Work from the Roach lab demonstrated that as phosphate levels increase in glycogen, glycogen becomes insoluble (Tagliabracci et al. 2008). Minassian and colleagues isolated glycogen from cells transfected with laforin and showed that LD-associated laforin mutations caused glycogen to transform into poorly branched, amylopectin-like aggregates (Tiberia et al. 2012). Furthermore, in mice, in the absence of laforin or malin, not only is glycogen accumulated, the structure, branching and chain length distribution of glycogen granules are altered (Nitschke et al. 2013; Valles-Ortega et al. 2011). Like plant starch, the aberrant glycogen that eventually forms LBs has less frequent branching, longer chain lengths, and higher phosphate levels, consistent with what was reported in the early histological studies of LD patient tissues in the 1960s (Gentry et al. 2009; Yokoi et al. 1968; Schnabel and Seitelberger 1968).

Cumulatively, these results strongly demonstrate that laforin regulates glycogen phosphate levels to inhibit LB formation (Fig. 2a). The origin of the phosphate in glycogen remains a matter of debate. A glycogen molecule can contain up to 55,000 glucose units with 1 phosphate per 500–2000 glucose moieties, depending on the source of the glycogen (reviewed in Roach et al. 2012). Phosphate is present as monoesters at the C2, C3, and C6 position of glucose moieties as reported by NMR and biochemical analyses (Fig. 2b) (Nitschke et al. 2013; Tagliabracci et al. 2011; DePaoli-Roach et al. 2014). The relative ratios of these modifications in glycogen are about equal (DePaoli-Roach et al. 2014). C2 and possibly C3 phosphate may occur via a rare side reaction of glycogen synthase that transfers the β phosphate of its substrate UDP-glucose to glycogen, but this probably only occurs once every ~10,000 cycles, accounting for only as much as a fifth of total phosphate, and this mechanism cannot account for the presence of C6 phosphate (Tagliabracci et al. 2011; Contreras et al. 2016). Plants possess glucan dikinases that directly phosphorylate starch, and although a glycogen kinase has been proposed, no such enzyme has yet been described (Nitschke et al. 2013; Roach et al. 2012). The Zeeman and Steup labs developed an assay utilizing plant starch that allows phosphate release from either C3 or C6 positions to be detected, but this assay cannot detect C2 phosphate since plant starch lacks C2 phosphate (Hejazi et al. 2010). Using this assay we showed that laforin dephosphorylates both C3 and C6 positions of glucose moieties with a preference for the C3 position (Meekins et al. 2015). In starch, C3 and C6 phosphate have different effects on the structure and orientation of the glucan chains, and C6 phosphate would potentially compete with branching; thus it is possible that in glycogen, C2, C3, and C6 phosphate play distinct roles in regulating the structure of the molecule (Roach et al. 2012; Blennow and Engelsen 2010).
Laforin, Fig. 2

(a) Glycogen is a soluble branched glucose polymer that contains up to 55,000 glucose units per molecule. EPM2A mutations lead to a loss of laforin activity and glycogen hyperphosphorylation. This results in formation of glycogen hyperphosphorylation, LB formation, and epilepsy. Image credit: (Dr. Antonio Zamora, www.scientificpsychic.com) (b) Location of phosphate in glycogen. Phosphate is covalently linked to the C2, C3, and C6 hydroxyls of glucose moieties in glycogen. (c) The X-ray crystal structure of dimeric, product bound laforin demonstrated the basis for specific glucan phosphatase activity. One subunit is shown in shades of blue and one in shades of pink. (Raththagala et al. 2015)

Regulation of Laforin Activity and Concentration

Multiple groups have shown that mutations in the CBM and DSP domain lead to a loss of phosphatase activity, while only mutations in the CBM lead to a loss of glycogen binding. It has now been established that laforin binding to glycogen is largely mediated by the CBM and dephosphorylation by the DSP domain (Raththagala et al. 2015; Dias et al. 2015). Our lab recently determined the X-ray crystal structure of laforin bound to phosphate and maltohexaose, a six-unit glucan that models the linear chains found in glycogen (Fig. 2c) (Raththagala et al. 2015). The structure revealed an antiparallel homodimer, with a dimer interface mediated exclusively by the DSP domains and an architecture that is unique among the glucan phosphatases (reviewed in Emanuelle et al. 2016; Gentry et al. 2016). The CBM and DSP domain of each subunit are tightly integrated, and LD mutations at this interface lead to increased interdomain dynamics and a loss of glycogen phosphatase activity, indicating the CBM-DSP interface is important for function (Raththagala et al. 2015). We also demonstrated that binding affinity increases with chain length, that dimerization is important for cooperative, high-affinity binding of long oligosaccharides, and that LD mutations have differential effects on laforin binding and phosphatase activity. These results support the notion that laforin preferentially targets long glucan chains like those found in LBs. Dimerization of laforin has been a matter of debate in the field, but the extended dimer interface in the crystal structure and solution-based experiments from multiple groups have confirmed that laforin is dimeric (Raththagala et al. 2015; Dukhande et al. 2011; Sanchez-Martin et al. 2013; Sankhala et al. 2014). Another group proposed the laforin structure with a CBM-CBM dimer interface, but this arrangement was determined using a partial structure containing only the DSP domain and homology modeling (Sankhala et al. 2014).

The RING-type E3 ubiquitin ligase malin binds and ubiquitinates laforin in cell culture (Gentry et al. 2005). The interaction between laforin and malin is mediated by the protein-interaction domain of malin containing six NHL (NCL-1, HT2A, and LIN-41 proteins) repeats (Gentry et al. 2005; Lohi et al. 2005). In overexpression systems, coexpression of laforin and malin leads to a decrease in laforin levels and inhibition of proteasome activity by MG132 results in increased laforin levels, indicating that laforin levels are regulated by the proteasome (Gentry et al. 2005; Mittal et al. 2007). In addition, malin ubiquitination of laforin was recapitulated using purified components in vitro (Gentry et al. 2005). In support of this finding, malin knockout (KO) mice display increased levels of laforin (Tiberia et al. 2012; Valles-Ortega et al. 2011; DePaoli-Roach et al. 2010). However, this presents a paradox since mutations in EPM2B, the gene encoding malin, also result in LD. If malin negatively regulates laforin, why do mutations in either gene lead to LB formation and LD? One hypothesis proposed by multiple groups in the field is that laforin and malin work in tandem: laforin first binds to glycogen and dephosphorylates it, and then laforin must be ubiquitinated by malin and removed before the construction of glycogen proceeds, preventing its entrapment in the glycogen macromolecule (Tiberia et al. 2012; Gentry et al. 2005). Another group proposed that laforin and malin are interdependent enzymes, laforin presenting itself as a substrate to prevent the autoubiquitination of malin, and malin ubiquitinating the phosphatase-inactive laforin monomer (Mittal et al. 2015). The answer to this question is still not clear, but there is evidence that in addition to their independent functions, laforin and malin may function as a complex (further discussed in “Interactions and Signaling”).

It is also important to note that laforin protein levels correlate with glycogen stores. Various transgenic mouse models with increased or decreased glycogen levels display parallel increases and decreases in laforin protein levels while laforin transcript levels are unchanged (Wang et al. 2006a). Glycogen synthase levels are increased in malin KO mice, and both glycogen synthase and laforin are associated with insoluble, accumulated glycogen (Tiberia et al. 2012; Valles-Ortega et al. 2011; DePaoli-Roach et al. 2010). Furthermore, laforin sediments with LBs via a low speed centrifugation step and colocalizes with LBs in histological sections from LD mouse models, suggesting laforin preferentially binds to LBs over glycogen (Tiberia et al. 2012; Criado et al. 2012; Chan et al. 2004).

Interactions and Signaling

There is increasing evidence that laforin and malin function as a complex to regulate the enzymes involved in glycogen metabolism. It has been reported that laforin is phosphorylated at Ser25 by AMP-activated protein kinase (AMPK), a major sensor of metabolic energy, and that AMPK phosphorylation increases the laforin-malin interaction (Roma-Mateo et al. 2011, McBride et al. 2009). Laforin interacts with Protein targeting to glycogen (PTG/R5) and R6, both regulatory subunits of protein phosphatase 1 (PP1), GS, and AMPK subunits, and has been shown to mediate the ubiquitination of these enzymes by malin (Fig. 3) (Vilchez et al. 2007; Worby et al. 2008; Rubio-Villena et al. 2013). Additionally, malin has also been shown to ubiquitinate glycogen debranching enzyme (GDE/AGL) in cell culture which may or may not require endogenous laforin (Cheng et al. 2007). However, except in the case of GS, the levels of the enzymes involved in glycogen metabolism are unchanged in LD mouse models, so it is unlikely that ubiquitination is targeting these enzymes for degradation (Wang et al. 2007). Further, like laforin, GS levels correlate with glycogen levels, so the increased laforin and GS observed in LD mice may be a result of increased glycogen rather than the lack of ubiquitination by malin. K63-linked ubiquitination has been shown to have nonproteasomal effects on protein substrates, and whenever the linkages are defined for these enzymes, as in the case of AMPK subunits and R6, ubiquitination by malin is always K63-linked (Rubio-Villena et al. 2013; Chen and Sun 2009; Roma-Mateo et al. 2011b). Furthermore, other proteins that are not involved in glycogen metabolism have been shown to be ubiquitinated by malin or the laforin-malin complex, including pyruvate kinase and the autophagy-related protein sequestosome-1/p62 (Sanchez-Martin et al. 2015; Viana et al. 2015). AMPK has also been reported to phosphorylate and regulate GS and PTG; thus, there is likely a complex regulatory interplay involving phosphorylation and ubiquitination occurring on the glycogen molecule (Vernia et al. 2009; Bultot et al. 2012).
Laforin, Fig. 3

Glycogen is remodeled by four enzymes: glycogen synthase (GS) which transfers the glucose moiety of UDP-glucose to glycogen, glycogen branching enzyme (GBE) which creates branch points, glycogen phosphorylase (GP) which utilizes ATP to release phosphorylated glucose from glycogen, and glycogen debranching enzyme (GDE/AGL) which removes branch points. Protein targeting to glycogen (PTG/R5) is a regulatory subunit of protein phosphatase 1 (PP1) that contains a CBM and targets PP1 to glycogen, where it dephosphorylates GS and GP, stimulating glycogen synthesis. AMP-activated protein kinase (AMPK) is heterotrimeric regulator of cellular activity and one of the enzymes that phosphorylates GS. The β-subunit of AMPK contains a CBM, targeting it to glycogen. The laforin-malin complex interacts with and ubiquitinates GS, PTG, GDE, and the β-subunit of AMPK. In multiple reports ubiquitination was identified as K63-linked, and likely does not result in the proteasomal degradation of these enzymes, as all but GS are unchanged in protein level in laforin and malin KO mice

Interestingly, the D146N malin mutation has been associated with a mild phenotype in LD patients, and this mutation has been reported to disrupt the interaction between laforin and malin (Vilchez et al. 2007). Based on these data, it is plausible that there are two ways in which laforin regulates glycogen metabolism: (1) by removing covalent phosphate and (2) by acting as a scaffold/adaptor protein for malin-mediated K63 ubiquitination. Perhaps K63 polyubiquitination affects the localization and/or activity of GS, PTG, GDE, and AMPK, but not protein levels; this would explain how malin could regulate these enzymes without promoting their degradation. Furthermore, malin is unique among E3 ubiquitin ligases in that it contains only a six-NHL domain in addition to its RING domain. Other RING-containing E3s typically contain additional substrate binding domains, such as the B-box or coiled-coil domain (Roma-Mateo et al. 2011). Laforin may function in place of these additional domains as an adaptor for malin substrates. This model would unify the present data, supporting both the presence of a complex and the independent roles of laforin as a glycogen phosphatase.

Multiple studies have described a link between laforin and autophagy, oxidative stress, glutamate transport and inflammation. A number of important studies were published describing autophagy defects in laforin- and malin-deficient mice, including lower levels of LC3-II, fewer autophagosomes, and higher levels of p62 (Criado et al. 2012; Aguado et al. 2010; Puri et al. 2012; Jain et al. 2016). These defects were observed as early as postnatal day 16 in mice, before the appearance of LBs. Interestingly, an increase in mTOR activation, which negatively regulates autophagy, was observed in the laforin KO mice, but not malin KO mice, and overexpression of laforin in cell culture increased autophagy and decreased mTOR activity (Aguado et al. 2010). However, subsequent studies have shown that the autophagy impairment in LD models is likely a secondary effect of glycogen accumulation as autophagic defects are reversed when glycogen synthesis is ablated (Garyali et al. 2014; Duran et al. 2014). Mouse models also indicate the absence of laforin or malin leads to increased numbers of reactive glia and microglia and increased expression of cytokines, decreased mitochondrial function and antioxidant enzymes, and altered glutamate transport (Roma-Mateo et al. 2014; Lopez-Gonzalez et al. 2016; Munoz-Ballester et al. 2016). These effects could be directly related to the absence of laforin or malin, or they could be secondary effects of aberrant glycogen metabolism and/or a loss of metabolic control in the cell.

In addition to dephosphorylating glycogen, some studies have reported that laforin interacts with and dephosphorylates glycogen synthase kinase3β (GSK3β) at serine-9 and modifies the function of GSK3β in Wnt signaling (Lohi et al. 2005; Wang et al. 2006). However, other groups have not observed interaction with GSK3β or its dephosphorylation by laforin (Wang et al. 2007; Worby et al. 2006). Additionally, one group showed that laforin dephosphorylates the microtubule-stabilizing protein tau, but this result has not been confirmed in vitro using purified components and could be an indirect effect (Puri et al. 2009).

The Role of Laforin in Lafora Disease

A number of recent studies from the Minassian, Roach and Guinovart labs have elegantly shown that glycogen accumulation is the pathogenic cause in LD (Fig. 2a). Protein targeting to glycogen (PTG) is a regulatory subunit of Protein Phosphatase 1 (PP1), which dephosphorylates glycogen synthase (GS) and glycogen phosphorylase (GP). GS promotes synthesis and GP promotes the breakdown of glycogen, and these enzymes are down and upregulated by phosphorylation, respectively. Thus, PTG acts through PP1 to promote glycogen synthesis. The Roach and Minassian lab generated mice lacking both laforin and PTG and showed that the double KO animals had normal glycogen levels and no signs of neurodegeneration, indicating they had rescued the disease (Turnbull et al. 2011). The same rescue was achieved by knocking out PTG and malin, or when glycogen synthesis was completely eliminated by knocking out GS and laforin or GS and malin; these mice have no LBs and no neurological impairments (Duran et al. 2014; Pederson et al. 2013; Turnbull et al. 2014). Furthermore, in cell culture, glycogen accumulation leads to neuronal cell death, and constitutive activation of GS in flies and mice leads to decreased lifespan, locomotion problems, and neuronal loss, indicating glycogen accumulation drives neurodegeneration (Vilchez et al. 2007; Duran et al. 2012). Thus, it is clear that the loss of laforin or malin causes LD due to a loss of control over glycogen metabolism.

How laforin and malin promote normal glycogen metabolism is still unclear, but laforin and malin may function both independently and as a complex to regulate glycogen metabolic enzymes (See “Interactions and Signaling”). The importance of the phosphatase activity of laforin has been challenged by a recent study in which a catalytically inactive laforin was ectopically expressed in laforin KO mice (Gayarre et al. 2014). However, this protein was grossly overexpressed, almost 100-fold more than endogenous laforin in the wild-type mice. If laforin regulates glycogen metabolism both via dephosphorylation and as an adaptor protein for malin, gross overexpression even of a catalytically inactive form may compensate for the loss of phosphatase activity through its role as an adaptor protein.

Studies from the 1990s recognized that glycogen contains trace amounts of phosphate (Lomako et al. 1994, 1993). One study proposed that the phosphate content of glycogen may be related to the age of the granule, and increased phosphate may be a metabolic marker that promoted lysosomal degradation of glycogen (Lomako et al. 1994). Glycogen is degraded via two pathways: by the action of GP and GDE and also via the lysosome in a process recently termed “glycophagy” (Jiang et al. 2011). Phosphate may be a marker to distinguish these two pathways. Further, a recent study reported that laforin and glycogen phosphate play a role in glycogen remodeling following exhausting exercise, since phosphate content remained suppressed in WT mice following glycogen depletion, and glycogen remodeling was delayed in laforin KO mice (Irimia et al. 2015).

In plants, glucose is stored in the form of starch; the long glucan chains form double helices that exclude water, rendering starch a densely packed, insoluble macromolecule that is inaccessible to the enzymes that break it down (Bertoft 2015). Phosphorylation of the outer chains at C6 and C3 positions by kinases promotes solubilization, providing access to starch hydrolytic enzymes (Blennow 2015; Smirnova et al. 2015; Pfister and Zeeman 2016). However, phosphorylation can also block the action of these enzymes, so the phosphatases SEX4 and LSF2 are also required to dephosphorylate the chains (Silver et al. 2014). The absence of a kinase or phosphatase in plants leads to a starch-excess phenotype, much like the absence of laforin leads to LB formation in humans and mice. Phosphate in glycogen is likely to play an analogous, although distinct, role in regulating its metabolism.

Recent studies have shown that glycogen plays an important and dynamic role in the brain (Brown 2004; Gibbs et al. 2007; Swanson et al. 1990; Sickmann et al. 2012; Dinuzzo et al. 2014a, b; Duran et al. 2013). Contrary to the long-held belief that only astrocytes can produce glycogen, Guinovart and coworkers have shown that neurons possess glycogen metabolic enzymes, but glycogen must be tightly regulated in neurons: neuronal glycogen promotes cell survival in hypoxic conditions while its accumulation leads to cell death (Valles-Ortega et al. 2011; Vilchez et al. 2007; Duran et al. 2014; Saez et al. 2014). Glycogen regulation is complex: the enzymes that directly remodel glycogen are controlled by reversible phosphorylation and allosteric modulators, and glycogen exists in distinct subcellular pools that vary in size and metabolic role. It is likely that there is a spatiotemporal element to its regulation by metabolic enzymes that may involve laforin and malin (Graham et al. 2010; Obel et al. 2012).


Laforin is a bimodular protein that contains an amino-terminal CBM followed by a DSP domain and is encoded by the EPM2A gene. Mutations in EPM2A result in LD. Laforin has a number of potential functions: binding to glycogen, dephosphorylating glycogen, acting as a scaffold on the glycogen molecule, and mediating ubiquitination by malin. With substantial in vitro biochemical data, mouse models, and studies in human patients, laforin is undisputedly a glucan phosphatase, and this enzyme class is conserved in many organisms, from protists to plants and humans, justifying its importance in many forms of life (Gentry et al. 2007, 2009; Gentry and Pace 2009). There are also numerous studies from many labs supporting the interaction of laforin with malin and various glycogen metabolic enzymes (Fig. 3). Although it is not yet clear how laforin is involved in the regulation of these enzymes, it is clear that LD centers on glycogen metabolism, in which laforin plays a critical role.


  1. Aguado C, Sarkar S, Korolchuk VI, Criado O, Vernia S, Boya P, et al. Laforin, the most common protein mutated in Lafora disease, regulates autophagy. Hum Mol Genet. 2010;19(14):2867–76.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Berkovic SF, Andermann F, Carpenter S, Wolfe LS. Progressive myoclonus epilepsies: specific causes and diagnosis. N Engl J Med. 1986;315(5):296–305.PubMedCrossRefGoogle Scholar
  3. Berkovic SF, So NK, Andermann F. Progressive myoclonus epilepsies: clinical and neurophysiological diagnosis. J Clin Neurophysiol. 1991;8(3):261–74.PubMedCrossRefGoogle Scholar
  4. Bertoft E. Fine structure of amylopectin. In: Starch: metabolism and structure. Tokyo: Springer; 2015. p. 3–40.CrossRefGoogle Scholar
  5. Blennow A. Phosphorylation of the starch granule. In: Starch. Springer: Tokyo; 2015. p. 399–424.CrossRefGoogle Scholar
  6. Blennow A, Engelsen SB. Helix-breaking news: fighting crystalline starch energy deposits in the cell. Trends Plant Sci. 2010;15(4):236–40.PubMedCrossRefGoogle Scholar
  7. Brewer MK, Husodo S, Dukhande VV, Johnson MB, Gentry MS. Expression, purification and characterization of soluble red rooster laforin as a fusion protein in Escherichia coli. BMC Biochem. 2014;15:8.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Brown AM. Brain glycogen re-awakened. J Neurochem. 2004;89(3):537–52.PubMedCrossRefGoogle Scholar
  9. Bultot L, Guigas B, Von Wilamowitz-Moellendorff A, Maisin L, Vertommen D, Hussain N, et al. AMP-activated protein kinase phosphorylates and inactivates liver glycogen synthase. Biochem J. 2012;443(1):193–203.PubMedCrossRefGoogle Scholar
  10. Cantarel BL, Coutinho PM, Rancurel C, Bernard T, Lombard V, Henrissat B. The Carbohydrate-Active EnZymes database (CAZy): an expert resource for Glycogenomics. Nucleic Acids Res. 2009;37(Database issue):D233–8.PubMedCrossRefGoogle Scholar
  11. Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, Christopoulos CC, et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet. 2003;35(2):125–7.PubMedCrossRefGoogle Scholar
  12. Chan EM, Ackerley CA, Lohi H, Ianzano L, Cortez MA, Shannon P, et al. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy. Hum Mol Genet. 2004;13(11):1117–29.PubMedCrossRefGoogle Scholar
  13. Chen ZJ, Sun LJ. Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell. 2009;33(3):275–86.PubMedCrossRefGoogle Scholar
  14. Cheng A, Zhang M, Gentry MS, Worby CA, Dixon JE, Saltiel AR. A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori’s disease. Genes Dev. 2007;21(19):2399–409.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Contreras CJ, Segvich DM, Mahalingan K, Chikwana VM, Kirley TL, Hurley TD, et al. Incorporation of phosphate into glycogen by glycogen synthase. Arch Biochem Biophys. 2016;597:21–9.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Criado O, Aguado C, Gayarre J, Duran-Trio L, Garcia-Cabrero AM, Vernia S, et al. Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy. Hum Mol Genet. 2012;21(7):1521–33.PubMedCrossRefGoogle Scholar
  17. DePaoli-Roach AA, Tagliabracci VS, Segvich DM, Meyer CM, Irimia JM, Roach PJ. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin. J Biol Chem. 2010;285(33):25372–81.PubMedPubMedCentralCrossRefGoogle Scholar
  18. DePaoli-Roach AA, Contreras CJ, Segvich DM, Heiss C, Ishihara M, Azadi P, et al. Glycogen phosphomonoester distribution in mouse models of the progressive myoclonic epilepsy, Lafora disease. J Biol Chem. 2014;290(2):841–50.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Dias DM, Furtado J, Wasielewski E, Cruz R, Costello B, Cole L, et al. Biophysical characterization of laforin-carbohydrate interaction. Biochem J. 2015;473(3):335–45.PubMedCrossRefGoogle Scholar
  20. Dinuzzo M, Mangia S, Maraviglia B, Giove F. Does abnormal glycogen structure contribute to increased susceptibility to seizures in epilepsy? Metab Brain Dis. 2014a;30(1):307–16.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Dinuzzo M, Mangia S, Maraviglia B, Giove F. Physiological bases of the K+ and the glutamate/GABA hypotheses of epilepsy. Epilepsy Res. 2014b;108(6):995–1012.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Dubey D, Ganesh S. Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy. Hum Mol Genet. 2008;17(19):3010–20.PubMedCrossRefGoogle Scholar
  23. Dubey D, Parihar R, Ganesh S. Identification and characterization of novel splice variants of the human EPM2A gene mutated in Lafora progressive myoclonus epilepsy. Genomics. 2012;99(1):36–43.PubMedCrossRefGoogle Scholar
  24. Dukhande VV, Sherwood AR, Gentry MS. Laforin- nature molecule page. In: Nature molecule pages. 2010. San Diego: Nature Signaling Gateway. doi:10.1038/mp.a000032.01.Google Scholar
  25. Dukhande VV, Rogers DM, Roma-Mateo C, Donderis J, Marina A, Taylor AO, et al. Laforin, a dual specificity phosphatase involved in Lafora disease, is present mainly as monomeric form with full phosphatase activity. PLoS One. 2011;6(8):e24040.PubMedPubMedCentralCrossRefGoogle Scholar
  26. Duran J, Tevy MF, Garcia-Rocha M, Calbo J, Milan M, Guinovart JJ. Deleterious effects of neuronal accumulation of glycogen in flies and mice. EMBO Mol Med. 2012;4(8):719–29.PubMedPubMedCentralCrossRefGoogle Scholar
  27. Duran J, Saez I, Gruart A, Guinovart JJ, Delgado-Garcia JM. Impairment in long-term memory formation and learning-dependent synaptic plasticity in mice lacking glycogen synthase in the brain. J Cereb Blood Flow Metab. 2013;33(4):550–6.PubMedPubMedCentralCrossRefGoogle Scholar
  28. Duran J, Gruart A, Garcia-Rocha M, Delgado-Garcia JM, Guinovart JJ. Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease. Hum Mol Genet. 2014;23(12):3147–56.PubMedCrossRefGoogle Scholar
  29. Emanuelle S, Brewer MK, Meekins DA, Gentry MS. Unique carbohydrate binding platforms employed by the glucan phosphatases. Cell Mol Life Sci. 2016;73(14):2765–78.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Fernandez-Sanchez ME, Criado-Garcia O, Heath KE, Garcia-Fojeda B, Medrano-Fernandez I, Gomez-Garre P, et al. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Hum Mol Genet. 2003;12(23):3161–71.PubMedCrossRefGoogle Scholar
  31. Ganesh S, Agarwala KL, Ueda K, Akagi T, Shoda K, Usui T, et al. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum Mol Genet. 2000;9(15):2251–61.PubMedCrossRefGoogle Scholar
  32. Ganesh S, Agarwala KL, Amano K, Suzuki T, Delgado-Escueta AV, Yamakawa K. Regional and developmental expression of Epm2a gene and its evolutionary conservation. Biochem Biophys Res Commun. 2001;283(5):1046–53.PubMedCrossRefGoogle Scholar
  33. Ganesh S, Suzuki T, Yamakawa K. Alternative splicing modulates subcellular localization of laforin. Biochem Biophys Res Commun. 2002;291(5):1134–7.PubMedCrossRefGoogle Scholar
  34. Ganesh S, Tsurutani N, Suzuki T, Hoshii Y, Ishihara T, Delgado-Escueta AV, et al. The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies. Biochem Biophys Res Commun. 2004;313(4):1101–9.PubMedCrossRefGoogle Scholar
  35. Ganesh S, Puri R, Singh S, Mittal S, Dubey D. Recent advances in the molecular basis of Lafora’s progressive myoclonus epilepsy. J Hum Genet. 2006;51(1):1–8.PubMedCrossRefGoogle Scholar
  36. Garyali P, Segvich DM, DePaoli-Roach AA, Roach PJ. Protein degradation and quality control in cells from laforin and malin knockout mice. J Biol Chem. 2014;289(30):20606–14.PubMedPubMedCentralCrossRefGoogle Scholar
  37. Gayarre J, Duran-Trio L, Criado Garcia O, Aguado C, Juana-Lopez L, Crespo I, et al. The phosphatase activity of laforin is dispensable to rescue Epm2a−/− mice from Lafora disease. Brain. 2014;137(Pt 3):806–18.PubMedCrossRefGoogle Scholar
  38. Gentry MS, Pace RM. Conservation of the glucan phosphatase laforin is linked to rates of molecular evolution and the glycogen metabolism of the organism. BMC Evol Biol. 2009;9(1):138.PubMedPubMedCentralCrossRefGoogle Scholar
  39. Gentry MS, Worby CA, Dixon JE. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc Natl Acad Sci USA. 2005;102(24):8501–6.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Gentry MS, Dowen 3rd RH, Worby CA, Mattoo S, Ecker JR, Dixon JE. The phosphatase laforin crosses evolutionary boundaries and links carbohydrate metabolism to neuronal disease. J Cell Biol. 2007;178(3):477–88.PubMedPubMedCentralCrossRefGoogle Scholar
  41. Gentry MS, Dixon JE, Worby CA. Lafora disease: insights into neurodegeneration from plant metabolism. Trends Biochem Sci. 2009;34(12):628–39.PubMedPubMedCentralCrossRefGoogle Scholar
  42. Gentry MS, Roma-Mateo C, Sanz P. Laforin, a protein with many faces: glucan phosphatase, adapter protein, et alii. FEBS J. 2013;280(2):525–37.PubMedCrossRefGoogle Scholar
  43. Gentry MS, Brewer MK, Vander Kooi CW. Structural biology of glucan phosphatases from humans to plants. Curr Opin Struct Biol. 2016;40:62–9.PubMedPubMedCentralCrossRefGoogle Scholar
  44. Gibbs ME, Lloyd HG, Santa T, Hertz L. Glycogen is a preferred glutamate precursor during learning in 1-day-old chick: biochemical and behavioral evidence. J Neurosci Res. 2007;85(15):3326–33.PubMedCrossRefGoogle Scholar
  45. Girard JM, Turnbull J, Ramachandran N, Minassian BA. Progressive myoclonus epilepsy. Handb Clin Neurol. 2013;113:1731–6.PubMedCrossRefGoogle Scholar
  46. Graham TE, Yuan Z, Hill AK, Wilson RJ. The regulation of muscle glycogen: the granule and its proteins. Acta Physiol (Oxford). 2010;199(4):489–98.CrossRefGoogle Scholar
  47. Hejazi M, Fettke J, Kotting O, Zeeman SC, Steup M. The Laforin-like dual-specificity phosphatase SEX4 from Arabidopsis hydrolyzes both C6- and C3-phosphate esters introduced by starch-related dikinases and thereby affects phase transition of alpha-glucans. Plant Physiol. 2010;152(2):711–22.PubMedPubMedCentralCrossRefGoogle Scholar
  48. Irimia JM, Tagliabracci VS, Meyer CM, Segvich DM, DePaoli-Roach AA, Roach PJ. Muscle glycogen remodeling and glycogen phosphate metabolism following exhaustive exercise of wild type and laforin knockout mice. J Biol Chem. 2015;290(37):22686–98.PubMedPubMedCentralCrossRefGoogle Scholar
  49. Jain N, Mishra R, Ganesh S. FoxO3a-mediated autophagy is down-regulated in the laforin deficient mice, an animal model for Lafora progressive myoclonus epilepsy. Biochem Biophys Res Commun. 2016;474(2):321–7.PubMedCrossRefGoogle Scholar
  50. Jiang S, Wells CD, Roach PJ. Starch-binding domain-containing protein 1 (Stbd1) and glycogen metabolism: identification of the Atg8 family interacting motif (AIM) in Stbd1 required for interaction with GABARAPL1. Biochem Biophys Res Commun. 2011;413(3):420–5.PubMedPubMedCentralCrossRefGoogle Scholar
  51. Kotting O, Santelia D, Edner C, Eicke S, Marthaler T, Gentry MS, et al. STARCH-EXCESS4 is a Laforin-like phosphoglucan phosphatase required for starch degradation in Arabidopsis thaliana. Plant Cell. 2009;21(1):334–46.PubMedPubMedCentralCrossRefGoogle Scholar
  52. Lohi H, Ianzano L, Zhao X-C, Chan EM, Turnbull J, Scherer SW, et al. Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. Hum Mol Genet. 2005;14(18):2727–36.PubMedCrossRefGoogle Scholar
  53. Lomako J, Lomako WM, Whelan WJ, Marchase RB. Glycogen contains phosphodiester groups that can be introduced by UDPglucose: glycogen glucose 1-phosphotransferase. FEBS Lett. 1993;329(3):263–7.PubMedCrossRefGoogle Scholar
  54. Lomako J, Lomako WM, Kirkman BR, Whelan WJ. The role of phosphate in muscle glycogen. Biofactors. 1994;4(3–4):167–71.PubMedGoogle Scholar
  55. Lopez-Gonzalez I, Viana R, Sanz P, Ferrer I. Inflammation in Lafora disease: evolution with disease progression in laforin and malin knock-out mouse models. Mol Neurobiol. 2016. [Epub ahead of print] DOI: 10.1007/s12035-016-9884-4.Google Scholar
  56. McBride A, Ghilagaber S, Nikolaev A, Hardie DG. The glycogen-binding domain on the AMPK beta subunit allows the kinase to act as a glycogen sensor. Cell Metab. 2009;9(1):23–34.PubMedPubMedCentralCrossRefGoogle Scholar
  57. Meekins DA, Raththagala M, Auger KD, Turner BD, Santelia D, Kotting O, et al. Mechanistic insights into glucan phosphatase activity against polyglucan substrates. J Biol Chem. 2015;290(38):23361–70.PubMedPubMedCentralCrossRefGoogle Scholar
  58. Meekins DA, Vander Kooi CW, Gentry MS. Structural mechanisms of plant glucan phosphatases in starch metabolism. FEBS J. 2016;283(13):2427–47.PubMedPubMedCentralCrossRefGoogle Scholar
  59. Minassian BA. Lafora’s disease: towards a clinical, pathologic, and molecular synthesis. Pediatr Neurol. 2001;25(1):21–9.PubMedCrossRefGoogle Scholar
  60. Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, Mungall AJ, et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet. 1998;20(2):171–4.PubMedCrossRefGoogle Scholar
  61. Minassian BA, Andrade DM, Ianzano L, Young EJ, Chan E, Ackerley CA, et al. Laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase. Ann Neurol. 2001;49(2):271–5.PubMedCrossRefGoogle Scholar
  62. Mittal S, Dubey D, Yamakawa K, Ganesh S. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum Mol Genet. 2007;16(7):753–62.PubMedCrossRefGoogle Scholar
  63. Mittal S, Upadhyay M, Singh PK, Parihar R, Ganesh S. Interdependence of laforin and malin proteins for their stability and functions could underlie the molecular basis of locus heterogeneity in Lafora disease. J Biosci. 2015;40(5):863–71.PubMedCrossRefGoogle Scholar
  64. Munoz-Ballester C, Berthier A, Viana R, Sanz P. Homeostasis of the astrocytic glutamate transporter GLT-1 is altered in mouse models of Lafora disease. Biochim Biophys Acta. 2016;1862(6):1074–83.PubMedPubMedCentralCrossRefGoogle Scholar
  65. Nitschke F, Wang P, Schmieder P, Girard JM, Awrey DE, Wang T, et al. Hyperphosphorylation of glucosyl c6 carbons and altered structure of glycogen in the neurodegenerative epilepsy lafora disease. Cell Metab. 2013;17(5):756–67.PubMedCrossRefGoogle Scholar
  66. Obel LF, Muller MS, Walls AB, Sickmann HM, Bak LK, Waagepetersen HS, et al. Brain glycogen-new perspectives on its metabolic function and regulation at the subcellular level. Front Neuroenergeti. 2012;4:3.CrossRefGoogle Scholar
  67. Pederson BA, Turnbull J, Epp JR, Weaver SA, Zhao X, Pencea N, et al. Inhibiting glycogen synthesis prevents Lafora disease in a mouse model. Ann Neurol. 2013;74(2):297–300.PubMedPubMedCentralGoogle Scholar
  68. Pfister B, Zeeman SC. Formation of starch in plant cells. Cell Mol Life Sci. 2016;73(14):2781–807.PubMedPubMedCentralCrossRefGoogle Scholar
  69. Puri R, Suzuki T, Yamakawa K, Ganesh S. Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease. J Biol Chem. 2009;284(34):22657–63.PubMedPubMedCentralCrossRefGoogle Scholar
  70. Puri R, Suzuki T, Yamakawa K, Ganesh S. Dysfunctions in endosomal-lysosomal and autophagy pathways underlie neuropathology in a mouse model for Lafora disease. Hum Mol Genet. 2012;21(1):175–84.PubMedCrossRefGoogle Scholar
  71. Raththagala M, Brewer MK, Parker MW, Sherwood AR, Wong BK, Hsu S, et al. Structural mechanism of laforin function in glycogen dephosphorylation and lafora disease. Mol Cell. 2015;57(2):261–72.PubMedCrossRefGoogle Scholar
  72. Roach PJ, Depaoli-Roach AA, Hurley TD, Tagliabracci VS. Glycogen and its metabolism: some new developments and old themes. Biochem J. 2012;441(3):763–87.PubMedPubMedCentralCrossRefGoogle Scholar
  73. Roma-Mateo C, Solaz-Fuster Mdel C, Gimeno-Alcaniz JV, Dukhande VV, Donderis J, Worby CA, et al. Laforin, a dual-specificity phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase. Biochem J. 2011a;439(2):265–75.PubMedPubMedCentralCrossRefGoogle Scholar
  74. Roma-Mateo C, Moreno D, Vernia S, Rubio T, Bridges TM, Gentry MS, et al. Lafora disease E3-ubiquitin ligase malin is related to TRIM32 at both the phylogenetic and functional level. BMC Evol Biol. 2011b;11:225.PubMedPubMedCentralCrossRefGoogle Scholar
  75. Roma-Mateo C, Aguado C, Garcia-Gimenez JL, Ibanez-Cabellos JS, Seco-Cervera M, Pallardo FV, et al. Increased oxidative stress and impaired antioxidant response in Lafora disease. Free Radic Biol Med. 2014;75(Suppl 1):S47.PubMedCrossRefGoogle Scholar
  76. Roma-Mateo C, Raththagala M, Gentry MS, Sanz P. Assessing the Biological Activity of the Glucan Phosphatase Laforin. Methods Mol Biol. 2016;1447:107–19.PubMedPubMedCentralCrossRefGoogle Scholar
  77. Rubio-Villena C, Garcia-Gimeno MA, Sanz P. Glycogenic activity of R6, a protein phosphatase 1 regulatory subunit, is modulated by the laforin-malin complex. Int J Biochem Cell Biol. 2013;45(7):1479–88.PubMedCrossRefGoogle Scholar
  78. Saez I, Duran J, Sinadinos C, Beltran A, Yanes O, Tevy MF, et al. Neurons have an active glycogen metabolism that contributes to tolerance to hypoxia. J Cereb Blood Flow Metab. 2014;34(6):945–55.PubMedPubMedCentralCrossRefGoogle Scholar
  79. Sakai M, Austin J, Witmer F, Trueb L. Studies in myoclonus epilepsy (Lafora body form). II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology. 1970;20(2):160–76.PubMedCrossRefGoogle Scholar
  80. Sanchez-Martin P, Raththagala M, Bridges TM, Husodo S, Gentry MS, Sanz P, et al. Dimerization of the glucan phosphatase laforin requires the participation of cysteine 329. PLoS One. 2013;8(7):e69523.PubMedPubMedCentralCrossRefGoogle Scholar
  81. Sanchez-Martin P, Roma-Mateo C, Viana R, Sanz P. Ubiquitin conjugating enzyme E2-N and sequestosome-1 (p62) are components of the ubiquitination process mediated by the malin-laforin E3-ubiquitin ligase complex. Int J Biochem Cell Biol. 2015;69:204–14.PubMedCrossRefGoogle Scholar
  82. Sankhala RS, Koksal AC, Ho L, Nitschke F, Minassian BA, Cingolani G. Dimeric quaternary structure of human laforin. J Biol Chem. 2014;290(8):4552–9.PubMedPubMedCentralCrossRefGoogle Scholar
  83. Santelia D, Kotting O, Seung D, Schubert M, Thalmann M, Bischof S, et al. The phosphoglucan phosphatase like sex Four2 dephosphorylates starch at the C3-position in Arabidopsis. Plant Cell. 2011;23(11):4096–111.PubMedPubMedCentralCrossRefGoogle Scholar
  84. Schnabel R, Seitelberger F. Histophysical and histochemical investigations of myoclonus bodies. Pathol Eur. 1968;3(2):218–26.PubMedGoogle Scholar
  85. Serratosa JM, Delgado-Escueta AV, Posada I, Shih S, Drury I, Berciano J, et al. The gene for progressive myoclonus epilepsy of the Lafora type maps to chromosome 6q. Hum Mol Genet. 1995;4(9):1657–63.PubMedCrossRefGoogle Scholar
  86. Sherwood AR, Paasch BC, Worby CA, Gentry MS. A malachite green-based assay to assess glucan phosphatase activity. Anal Biochem. 2013;435(1):54–6.PubMedCrossRefGoogle Scholar
  87. Sickmann HM, Waagepetersen HS, Schousboe A, Benie AJ, Bouman SD. Brain glycogen and its role in supporting glutamate and GABA homeostasis in a type 2 diabetes rat model. Neurochem Int. 2012;60(3):267–75.PubMedCrossRefGoogle Scholar
  88. Silver DM, Kotting O, Moorhead GB. Phosphoglucan phosphatase function sheds light on starch degradation. Trends Plant Sci. 2014;19(7):471–8.PubMedCrossRefGoogle Scholar
  89. Singh PK, Singh S, Ganesh S. The laforin-malin complex negatively regulates glycogen synthesis by modulating cellular glucose uptake via glucose transporters. Mol Cell Biol. 2012;32(3):652–63.PubMedPubMedCentralCrossRefGoogle Scholar
  90. Smirnova J, Fernie AR, Steup M. Starch degradation. In: Starch: metabolism and structure. Tokyo: Springer; 2015. p. 239–90.CrossRefGoogle Scholar
  91. Swanson RA, Yu AC, Chan PH, Sharp FR. Glutamate increases glycogen content and reduces glucose utilization in primary astrocyte culture. J Neurochem. 1990;54(2):490–6.PubMedCrossRefGoogle Scholar
  92. Tagliabracci VS, Turnbull J, Wang W, Girard JM, Zhao X, Skurat AV, et al. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc Natl Acad Sci USA. 2007;104(49):19262–6.PubMedPubMedCentralCrossRefGoogle Scholar
  93. Tagliabracci VS, Girard JM, Segvich D, Meyer C, Turnbull J, Zhao X, et al. Abnormal metabolism of glycogen phosphate as a cause for lafora disease. J Biol Chem. 2008;283(49):33816–25.Google Scholar
  94. Tagliabracci VS, Heiss C, Karthik C, Contreras CJ, Glushka J, Ishihara M, et al. Phosphate incorporation during glycogen synthesis and Lafora disease. Cell Metab. 2011;13(3):274–82.PubMedPubMedCentralCrossRefGoogle Scholar
  95. Tiberia E, Turnbull J, Wang T, Ruggieri A, Zhao XC, Pencea N, et al. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease. J Biol Chem. 2012;287(30):25650–9.PubMedPubMedCentralCrossRefGoogle Scholar
  96. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006;7(11):833–46.PubMedCrossRefGoogle Scholar
  97. Turnbull J, Depaoli-Roach AA, Zhao X, Cortez MA, Pencea N, Tiberia E, et al. PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease. PLoS Genet. 2011;7(4):e1002037.PubMedPubMedCentralCrossRefGoogle Scholar
  98. Turnbull J, Epp JR, Goldsmith D, Zhao X, Pencea N, Wang P, et al. PTG protein depletion rescues malin-deficient Lafora disease in mouse. Ann Neurol. 2014;75(3):442–6.PubMedCrossRefGoogle Scholar
  99. Valles-Ortega J, Duran J, Garcia-Rocha M, Bosch C, Saez I, Pujadas L, et al. Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease. EMBO Mol Med. 2011;3(11):667–81.PubMedPubMedCentralCrossRefGoogle Scholar
  100. Vernia S, Solaz-Fuster MC, Gimeno-Alcaniz JV, Rubio T, Garcia-Haro L, Foretz M, et al. AMP-activated protein kinase phosphorylates R5/PTG, the glycogen targeting subunt of the R5/PTG-PP1 holoenzyme and accelerates its downregulation by the laforin-malin complex. J Biol Chem. 2009;284(13):8247–55.PubMedPubMedCentralCrossRefGoogle Scholar
  101. Viana R, Lujan P, Sanz P. The laforin/malin E3-ubiquitin ligase complex ubiquitinates pyruvate kinase M1/M2. BMC Biochem. 2015;16:24.PubMedPubMedCentralCrossRefGoogle Scholar
  102. Vilchez D, Ros S, Cifuentes D, Pujadas L, Valles J, Garcia-Fojeda B, et al. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat Neurosci. 2007;10(11):1407–13.PubMedCrossRefGoogle Scholar
  103. Wang W, Roach PJ. Glycogen and related polysaccharides inhibit the laforin dual-specificity protein phosphatase. Biochem Biophys Res Commun. 2004;325(3):726–30.PubMedCrossRefGoogle Scholar
  104. Wang J, Stuckey JA, Wishart MJ, Dixon JE. A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen. J Biol Chem. 2002;277(4):2377–80.PubMedCrossRefGoogle Scholar
  105. Wang W, Parker GE, Skurat AV, Raben N, DePaoli-Roach AA, Roach PJ. Relationship between glycogen accumulation and the laforin dual specificity phosphatase. Biochem Biophys Res Commun. 2006a;350(3):588–92.PubMedPubMedCentralCrossRefGoogle Scholar
  106. Wang Y, Liu Y, Wu C, Zhang H, Zheng X, Zheng Z, et al. Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling. Cancer Cell. 2006b;10(3):179–90.PubMedCrossRefGoogle Scholar
  107. Wang W, Lohi H, Skurat AV, Depaoli-Roach AA, Minassian BA, Roach PJ. Glycogen metabolism in tissues from a mouse model of Lafora disease. Arch Biochem Biophys. 2007;457(2):264–9.PubMedCrossRefGoogle Scholar
  108. Worby CA, Gentry MS, Dixon JE. Laforin: a dual specificity phosphatase that dephosphorylates complex carbohydrates. J Biol Chem. 2006;281(41):30412–8.PubMedPubMedCentralCrossRefGoogle Scholar
  109. Worby CA, Gentry MS, Dixon JE. Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). J Biol Chem. 2008;283(7):4069–76.PubMedCrossRefGoogle Scholar
  110. Yokoi S, Austin J, Witmer F, Sakai M. Studies in myoclonus epilepsy (Lafora body form). I. Isolation and preliminary characterization of Lafora bodies in two cases. Arch Neurol. 1968;19(1):15–33.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • M. Kathryn Brewer
    • 1
  • Amanda R. Sherwood
    • 1
  • Vikas V. Dukhande
    • 2
  • Matthew S. Gentry
    • 1
  1. 1.Department of Molecular and Cellular BiochemistryUniversity of Kentucky College of MedicineLexingtonUSA
  2. 2.Department of Pharmaceutical Sciences, College of Pharmacy and Health SciencesSt. John’s UniversityJamaicaUSA